Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

An anxious generation turns to functional foods and beverages and alternative medicine, inspiring better-for-you innovation.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

Oprah Winfrey reflects on past misconceptions about weight, admitting that a GLP-1 drug shifted her perspective.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Oprah Winfrey has opened up about one thing she got wrong about ‘thin people’ after taking weight loss drugs on her podcast.